Ascidians: an invertebrate chordate model to study Alzheimer's disease pathogenesis.
Here we present the ascidian Ciona intestinalis as an alternative invertebrate system to study Alzheimer's disease (AD) pathogenesis. Through the use of AD animal models, researchers often attempt to reproduce various aspects of the disease, particularly the coordinated processing of the amyloid precursor protein (APP) by alpha-, beta- and gamma-secretases to generate amyloid beta (Abeta)-containing plaques. Recently, Drosophila and C. elegans AD models have been developed, exploiting the relative simplicity of these invertebrate systems, but they lack a functional Abeta sequence and a beta-secretase ortholog, thus complicating efforts to examine APP processing in vivo. We propose that the ascidian is a more appropriate invertebrate AD model owing to their phylogenetic relationship with humans. This is supported by bioinformatic analyses, which indicate that the ascidian genome contains orthologs of all AD-relevant genes. We report that transgenic ascidian larvae can properly process human APP(695) to generate Abeta peptides. Furthermore, Abeta can rapidly aggregate to form amyloid-like plaques, and plaque deposition is significantly increased in larvae expressing a human APP(695) variant associated with familial Alzheimer's disease. We also demonstrate that nervous system-specific Abeta expression alters normal larval behavior during attachment. Importantly, plaque formation and alterations in behavior are not only observed within 24 hours post-fertilization, but anti-amyloid drug treatment improves these AD-like pathologies. This ascidian model for AD provides a powerful and rapid system to study APP processing, Abeta plaque formation and behavioral alterations, and could aid in identifying factors that modulate amyloid deposition and the associated disruption of normal cellular function and behaviors.
Virata
Michael J
MJ
Center for Applied and Experimental Genomics, San Diego State University, 5500 Campanile Drive, San Diego, California 92182-4614, USA.
Zeller
Robert W
RW
D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000737:chemistry / Q000378:metabolism; D000818:Animals; D030801:Animals, Genetically Modified; D001522:Behavior, Animal; D017124:Conserved Sequence; D004195:Disease Models, Animal; D004625:Embryo, Nonmammalian / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007814:Larva; D008969:Molecular Sequence Data; D058225:Plaque, Amyloid / Q000473:pathology; D011499:Protein Processing, Post-Translational; D014561:Urochordata / Q000378:metabolism*
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor